DK1163002T3 - Polykationiske kulhydrater som immunstimulanser i vacciner - Google Patents

Polykationiske kulhydrater som immunstimulanser i vacciner

Info

Publication number
DK1163002T3
DK1163002T3 DK00912788T DK00912788T DK1163002T3 DK 1163002 T3 DK1163002 T3 DK 1163002T3 DK 00912788 T DK00912788 T DK 00912788T DK 00912788 T DK00912788 T DK 00912788T DK 1163002 T3 DK1163002 T3 DK 1163002T3
Authority
DK
Denmark
Prior art keywords
vaccines
polycationic
carbohydrates
immune stimulants
polycationic carbohydrates
Prior art date
Application number
DK00912788T
Other languages
Danish (da)
English (en)
Inventor
Satyanarayana Somavarapu
Ethel Diane Williamson
Hazire Oya Alpar
James Edward Eyles
Leslie William James Baillie
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906694.6A external-priority patent/GB9906694D0/en
Priority claimed from GBGB9906696.1A external-priority patent/GB9906696D0/en
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of DK1163002T3 publication Critical patent/DK1163002T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00912788T 1999-03-24 2000-03-23 Polykationiske kulhydrater som immunstimulanser i vacciner DK1163002T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906694.6A GB9906694D0 (en) 1999-03-24 1999-03-24 Vaccine composition
GBGB9906696.1A GB9906696D0 (en) 1999-03-24 1999-03-24 Vaccine composition
PCT/GB2000/001118 WO2000056362A2 (en) 1999-03-24 2000-03-23 Polycationic carbohydrates as immunostimulants in vaccines

Publications (1)

Publication Number Publication Date
DK1163002T3 true DK1163002T3 (da) 2009-01-19

Family

ID=26315329

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912788T DK1163002T3 (da) 1999-03-24 2000-03-23 Polykationiske kulhydrater som immunstimulanser i vacciner

Country Status (11)

Country Link
US (1) US20080057083A1 (enExample)
EP (2) EP1163001A2 (enExample)
JP (3) JP5124066B2 (enExample)
AT (1) ATE403436T1 (enExample)
AU (2) AU762078B2 (enExample)
CA (2) CA2366216C (enExample)
DE (1) DE60039754D1 (enExample)
DK (1) DK1163002T3 (enExample)
ES (1) ES2311451T3 (enExample)
NZ (1) NZ514323A (enExample)
WO (2) WO2000056361A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780182B2 (en) * 2000-03-22 2005-03-03 Secretary Of State For Defence, The Pharmaceutical composition for administration to mucosal surfaces
WO2001098206A1 (en) 2000-06-22 2001-12-27 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
WO2002000173A2 (en) 2000-06-26 2002-01-03 Rxkinetix, Inc. Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
AU2002354644C1 (en) * 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
JP2005501845A (ja) 2001-08-16 2005-01-20 メディカル リサーチ カウンシル キチン微小粒子およびそれらの医学的用途
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
CA2643322C (en) * 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
JPWO2008041703A1 (ja) * 2006-10-02 2010-02-04 国立大学法人大阪大学 インフルエンザワクチン用アジュバントおよびインフルエンザワクチン
JP5297009B2 (ja) * 2007-07-24 2013-09-25 大日精化工業株式会社 免疫アジュバント水溶液
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
GB0721937D0 (en) 2007-11-08 2007-12-19 Secr Defence Rodenticide
US20110280949A1 (en) * 2008-08-06 2011-11-17 Padma Malyala Microparticles for use in immunogenic compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
KR101670340B1 (ko) * 2011-05-18 2016-10-28 매트리백스 인코포레이티드 폴리양이온을 포함하는 단백질 매트릭스 백신 조성물
US10500283B2 (en) 2011-05-30 2019-12-10 National Institute Of Immunology Vaccine composition capable of inducing memory antibody response from single point immunization
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
CN107899021A (zh) * 2017-11-06 2018-04-13 扬州大学 一种表面修饰s‑层蛋白的壳聚糖微球、制备及应用
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도
EP3960203A1 (en) 2020-08-25 2022-03-02 Université de Liège Complexes for the delivery of proteinaceous agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
GB1290141A (enExample) * 1968-05-31 1972-09-20
FR2306684A1 (fr) * 1975-04-11 1976-11-05 Crinex Lab Nouvelle composition a action immunostimulante
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
DE69015222T2 (de) * 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
EP0805678B1 (en) * 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
CA2215203C (en) * 1995-03-13 2008-12-09 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccines for plague
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9810126D0 (enExample) * 1998-05-13 1998-07-08 Glaxo Group Ltd
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US20030171258A1 (en) * 1999-03-24 2003-09-11 Alpar Hazire Oya Particle based vaccine composition
US20020103165A1 (en) * 2000-02-29 2002-08-01 Alliance Pharmaceutical Corp., Engineered spray-dried lipid-based microparticles for cellular targeting
AU780182B2 (en) * 2000-03-22 2005-03-03 Secretary Of State For Defence, The Pharmaceutical composition for administration to mucosal surfaces
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition

Also Published As

Publication number Publication date
AU755502B2 (en) 2002-12-12
ATE403436T1 (de) 2008-08-15
AU762078B2 (en) 2003-06-19
JP2012031186A (ja) 2012-02-16
CA2366216A1 (en) 2000-09-28
JP5124066B2 (ja) 2013-01-23
WO2000056361A2 (en) 2000-09-28
WO2000056361A3 (en) 2001-03-01
EP1163001A2 (en) 2001-12-19
WO2000056362A2 (en) 2000-09-28
AU755502C (en) 2003-08-14
EP1163002B1 (en) 2008-08-06
NZ514323A (en) 2003-03-28
WO2000056362A3 (en) 2001-02-01
JP2002540076A (ja) 2002-11-26
CA2366216C (en) 2012-10-23
EP1163002A2 (en) 2001-12-19
US20080057083A1 (en) 2008-03-06
DE60039754D1 (de) 2008-09-18
ES2311451T3 (es) 2009-02-16
CA2366908A1 (en) 2000-09-28
AU3443500A (en) 2000-10-09
AU3442400A (en) 2000-10-09
JP2002540077A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
DK1163002T3 (da) Polykationiske kulhydrater som immunstimulanser i vacciner
IL145982A0 (en) Vaccines
GB0025577D0 (en) Vaccine
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MY129263A (en) Vaccine composition
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
EP1352895A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MY127452A (en) Vaccines.
MXPA04001912A (es) Aminobenzofenonas novedosas.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2000057919A3 (en) Lipid-based artificial particles inducing cell-mediated immunity
HU0200980D0 (enExample)
UA38352A (uk) Засіб для лікувальних ванн
GEU2001787Y (en) Medicinal Tea
UA29558C2 (uk) Препарат для лікування бронхіальної астми " еуфілін-н 200"
GEP20012600B (en) Preparation for Treatment of Dysentery